Emphasizes Value of Domestic Production of Critical Medical Devices FRANKLIN LAKES, N.J., Aug. 22, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today celebrated the 75th anniversary of its manufacturing operations in Columbus, Neb., and reinforced the need for and value of domestic production for critical medical devices. BD first opened its doors in Columbus, Nebraska in 1949 with 15 employees in this 25,000 sq. ft. facility, manufacturin ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zac ...

FRANKLIN LAKES, N.J., Aug. 12, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that Michael Feld has been named executive vice president and president of the Life Sciences segment for BD, effective Aug. 20, 2024, and will serve as a member of the Executive Leadership Team. He succeeds Dave Hickey, who retired from BD last month after 10 years with the company. Michael Feld has been named executive vice president and president ...

FRANKLIN LAKES, N.J., Aug. 8, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Wells Fargo 2024 Healthcare Conference on Wednesday, September 4, 2024 at 8:45 am Eastern Time. The live webcast of BD's presentation can be accessed from the BD investor relations website, investors.bd.com. A replay of the event will be available on the same webpage following its conclusion. About BD BD is one of the larg ...

Monty Rakusen Becton, Dickinson and Company (NYSE:BDX) has made impressive gains overall over the last three weeks, rising from a low of $218.75 on July 10, 2024 to close at $241.87 on August 2, 2024. Although much of the market also made big gains during those days, it is nevertheless significant that BDX continued to go up on August 2 when the S&P 500 and most stocks overall fell in reaction to an underwhelming jobs report for July. Last Friday, August 2, the Dow was down by 1.5%, the S&P 500 index by 1.8 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-4802 Becton, Dickinson and Company (Exact name of registrant as specified in its charter) New Jersey 22-0760120 (State or other j ...

Becton, Dickinson and Company (BDX) , popularly known as BD, delivered adjusted earnings per share (EPS) of $3.50 in the third quarter of fiscal 2024, up 18.2% year over year. The figure topped the Zacks Consensus Estimate by 5.7%. The adjustments include expenses related to purchase accounting adjustments and integration costs, among others. GAAP EPS for the quarter was $1.68, reflecting an improvement of 23.5% from the year-earlier figure. Revenues in Detail BD registered revenues of $4.99 billion in the ...

Financial Data and Key Metrics Changes - The company reported a mid-single-digit organic revenue growth of 5.2% for Q3 2024, driven by strong volume and share gains across the portfolio [5][21] - Adjusted gross margin increased to 54.3%, and adjusted operating margin rose to 25.2%, reflecting a year-over-year increase of 170 basis points and 220 basis points respectively [24] - Adjusted diluted EPS grew by 18.2% year-over-year, reaching $3.50 [24] Business Line Data and Key Metrics Changes - BD Medical segment growth was led by strong performance in infusion systems, particularly the BD Alaris, which returned to market [21] - Pharmaceutical Systems experienced double-digit growth in prefilled devices for biologic drugs, primarily GLP-1s, despite some transitory market dynamics [22][13] - BD Life Sciences saw high single-digit growth in specimen management, although it faced lower market demand for instruments due to transitory dynamics [22] - BD Interventional reported high single-digit growth in UCC, with continued double-digit growth in the PureWick franchise [23] Market Data and Key Metrics Changes - Over 90% of the company's revenue grew by more than 6% organically across its three largest geographies, although there was a decrease in China due to ongoing market dynamics [21] - The company noted strong volume growth in MDS in China, despite price pressure from VBP dynamics [65] Company Strategy and Development Direction - The company is advancing its BD 2025 strategy, focusing on growth through innovation and tuck-in M&A, simplification through BD Excellence, and empowering the organization [6][19] - The acquisition of Critical Care is expected to enhance the connected care strategy and contribute to margin and earnings growth [7] - The company aims to expand its healthcare automation and informatics AI business to over $5 billion, with a long-term view of exceeding $7 billion by 2030 [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to outperform market dynamics and achieve strong financial performance in FY '25, despite ongoing challenges in certain markets [28][29] - The company anticipates continued strong performance in the connected medication management portfolio, particularly with Alaris, and expects to exceed its adjusted operating margin goal of 25% [28][37] Other Important Information - The company has achieved over 100% year-to-date growth in free cash flow, with a conversion rate above 80% [6][25] - The company is on track to reduce its manufacturing network by over 20% and is investing in smart factories to enhance productivity [18][19] Q&A Session Summary Question: Guidance for Q4 and revenue expectations - Management indicated that Q4 revenue guidance implies upper 6% organic growth, driven by continued momentum from Alaris and favorable comparisons from the previous year [30][33] Question: Revenue growth drivers beyond Alaris - Management highlighted strong growth in consumables and upcoming product launches, including the next-generation Pyxis platform, as key growth drivers beyond Alaris [52][53] Question: Dynamics in China and market recovery - Management noted that while there are transitory dynamics affecting performance in China, they expect long-term recovery in research investment and continued strong volume growth in MDS [64][65]

Becton Dickinson (BDX) reported $4.99 billion in revenue for the quarter ended June 2024, representing a yearover-year increase of 2.3%. EPS of $3.50 for the same period compares to $2.96 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $5.07 billion, representing a surprise of -1.57%. The company delivered an EPS surprise of +5.74%, with the consensus EPS estimate being $3.31. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and ...

Becton Dickinson (BDX) came out with quarterly earnings of $3.50 per share, beating the Zacks Consensus Estimate of $3.31 per share. This compares to earnings of $2.96 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 5.74%. A quarter ago, it was expected that this medical device manufacturer would post earnings of $2.96 per share when it actually produced earnings of $3.17, delivering a surprise of 7.09%. Over the last four qu ...